12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Perjeta pertuzumab regulatory update

FDA updated the label of Roche's Perjeta pertuzumab to include updated overall survival (OS) data from the Phase III CLEOPATRA trial in previously untreated HER2-positive metastatic or locally recurrent unresectable breast cancer patients. Specifically, OS data from a second interim analysis of the double-blind, international CLEOPATRA trial in 808 patients showed IV Perjeta every 3 weeks...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >